RxDoctor Payments Data

Victoria Lazareth, NP

Adult Health · South Portland, MENPI 1497729297

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,032 of the $12,227 with a category attached, or 73.9%. 16 manufacturers reported payments, led by Incyte Corporation at 44.8% of the total. Reporting peaked in 2023 at $6,683 and has fallen 99.5% since, to $33 in 2025. Among adult health clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,227in general payments, 2019–2025

Across 120 payments — averaging $101.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$5K
  • LEO Pharma Inc.$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • UCB, Inc.$1K
  • Boehringer Ingelheim$1K
  • AbbVie$345
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$9,03274%
  • Travel & lodging$8687%
  • Food & beverage$2,31919%
  • Education$80%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,227 in reported general payments places this provider in the 95th percentile of 51 adult health providers in Maine.

See all adult health providers in Maine

Medicare billing

Part B allowed, 2024
$199,613
Medicare patients
652
Services billed
3,207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa19$373,169
OtezlaApremilast22$96,321
Dupixent PenDupilumab13$47,021
Clobetasol Propionate66$4,025
Doxycycline Hyclate47$1,295
Triamcinolone Acetonide56$1,041
Ketoconazole47$918
Metronidazole16$815
Ammonium Lactate28$495
Clindamycin Phosphate13$414
Hydrocortisone18$268
Glycopyrrolate12$163
Mupirocin22$149
Minoxidil14$126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$18$96,32122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 51 adult health providers in Maine.

Other adult health in South Portland

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →